Business
Kodiak Sciences Announces Second Quarter 2019 Financial Results and Recent Business Highlights
PALO ALTO, Calif., Aug. 14, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel
About this update from Kodiak Sciences Inc
[{"type":"text","content":"PALO ALTO, Calif., Aug. 14, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today reported business highlights and financial results for the second quarter ended June 30, 2019.\n\"During the second quarter, we expanded enrollment in our Phase 1b study of KSI-301 across all three major retinal vascular disease indications of wet AMD, diabetic macular edema, and retinal vein occlusion. Last month we presented interim safety and efficacy results on the podium at the American Society of Retina Specialists (ASRS) 2019 Annual Meeting. Across all three diseases under study, we observed strong improvements in vision and retinal anatomy and encouraging signs of disease modification,\" said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. \"Additionally, this quarter we look forward to initiating our pivotal Phase 2 DAZZLE study of KSI-301 head-to-head versus aflibercept in patients with treatment-naïve wet AMD, with all patients randomized to KSI-301 on an every 12-week or longer dosing regimen after three monthly loading doses. We are excited by the growing body of promising safety and efficacy data on KSI-301, the opportunities to present evolving durability data at upcoming ophthalmology meetings, and our expanding set of clinical studies with the molecule.\"\nRecent Business Highlights:\nPositive Data from Ongoing Phase 1b Study of KSI-301 Presented at ASRS 2019 MeetingThe first data from the ongoing Phase 1b study of KSI-301 in patients with anti-VEGF treatment-naïve neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema due to retinal vein occlusion (RVO) were presented at the American Society of Retina Specialists (ASRS) 2019 Annual Meeting. Across all three diseases under study, strong improvements in vision and retinal anatomy were observed over 12 weeks. The efficacy data presented at ASRS include outcomes from 35 patients in the study who had reached the week 12 visit. In the study, patients are being treated with three monthly doses of either 2.5 mg or 5 mg KSI-301 and followed for 7 months thereafter, with additional treatments according to protocol-specified retreatment criteria. As of the July 24, 2019 ASRS presentatio...